TrialJAMA network open2023

Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy-Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial.

Qi Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.